Compass Therapeutics, Inc.
CMPX
$1.78
$0.031.71%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.54% | 18.96% | 17.37% | 3.84% | 5.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.12% | 17.62% | 15.35% | 20.92% | 20.91% |
| Operating Income | -12.43% | -15.85% | -13.60% | -20.92% | -20.91% |
| Income Before Tax | -16.20% | -17.42% | -10.68% | -13.89% | -8.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.20% | -17.42% | -10.68% | -13.89% | -8.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.20% | -17.42% | -10.68% | -13.89% | -8.33% |
| EBIT | -12.43% | -15.85% | -13.60% | -20.92% | -20.91% |
| EBITDA | -12.83% | -16.36% | -14.11% | -21.66% | -21.52% |
| EPS Basic | -6.19% | -9.42% | 2.00% | 2.33% | 9.23% |
| Normalized Basic EPS | -6.18% | -9.43% | 1.95% | 2.50% | 9.36% |
| EPS Diluted | -6.19% | -9.42% | 2.00% | 2.33% | 9.23% |
| Normalized Diluted EPS | -6.18% | -9.43% | 1.95% | 2.50% | 9.36% |
| Average Basic Shares Outstanding | 9.14% | 7.51% | 11.39% | 15.41% | 19.99% |
| Average Diluted Shares Outstanding | 9.14% | 7.51% | 11.39% | 15.41% | 19.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |